Targeting the LKB1-AMPK pathway has shown to inhibit tumor growth (Nagalingam et al., 2012), and the findings here provide rationale for SNRK as a target at the interface of metabolism and angiogenesis associated with tumor growth. Here, PRKAA2 is linked to neoplasm.